Haematology and Thrombosis Unit, Department of Rare, Immunologic, Hematologic Diseases and Transfusion Medicine, Giovanni Bosco Hospital, Turin, Italy.
Autoimmun Rev. 2013 Jun;12(8):826-31. doi: 10.1016/j.autrev.2012.11.007. Epub 2012 Dec 4.
In APS vascular patients, thrombotic recurrences are more frequent than in non-APS thrombotic patients. To better define this clinical setting, a systematic review of the literature after 1999 was performed: 8 cohort studies (including the recent APS Piedmont Cohort) and 6 intervention studies were selected and evaluated. Thrombotic recurrences, bleeding events, therapeutic strategies, antiphospholipid (aPL) profile, inherited and acquired risk factors (when present) were calculated and compared. Emerging risk factors for thrombotic recurrences include withdrawal of oral anticoagulant therapy (OAT), high intensity OAT (INR range 3-4), aPL profile (triple positivity, Miyakis types 1 and 2a profiles) and association with inherited or acquired pro-thrombotic risk factors. Moreover, there are evidences that high risk (mainly for aPL profile) APS vascular patients have a high recurrence rate in spite of correct OAT treatment. Clinical trials in this clinical setting are needed.
在抗磷脂综合征(APS)血管患者中,血栓复发比非 APS 血栓患者更为常见。为了更好地定义这种临床情况,我们对 1999 年后的文献进行了系统回顾:选择并评估了 8 项队列研究(包括最近的 APS 皮埃蒙特队列研究)和 6 项干预研究。计算并比较了血栓复发、出血事件、治疗策略、抗磷脂(aPL)谱、遗传性和获得性危险因素(如果存在)。血栓复发的新出现危险因素包括停用口服抗凝治疗(OAT)、高强度 OAT(INR 范围 3-4)、aPL 谱(三联阳性、Miyakis 1 型和 2a 谱)以及与遗传性或获得性促血栓形成危险因素的关联。此外,有证据表明,即使接受了正确的 OAT 治疗,高风险(主要与 aPL 谱有关)的 APS 血管患者的复发率仍然很高。需要在这种临床情况下开展临床试验。